TRACT Therapeutics is a biotechnology company developing immunotherapies using T regulatory cells to improve organ transplant outcomes that is headquartered in Chicago, Illinois and was founded in 2014 by Joseph Leventhal.
Cellular therapy is the core of TRACT Therapeutics focus as their proprietary technology has been developed in order to help restore the immune balance of patients that have received a solid organ transplant, as well as those with autoimmune diseases. The approach that was developed by TRACT to provide the therapeutics is based on a platform that also treats solid organ transplant patients and those with Crohn's Disease.
The treatment processes that TRACT uses to operate are started as soon as a patient that needs an organ transplant(s) can undergo a pre-transplant blood donation. TRACT provides the patient with cryopreserved white blood cells that are maintained through a proprietary process. The white blood cells are administered in order to down regulate transplant rejection as well as reduce and prevent inflammation.
TRACT's process was developed over the span of twenty years, and now involves the isolation and expansion of a patient's own naturally occurring T regulatory cells (Tregs).
TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient's Immune Cells to Prevent Organ Rejection
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.